Discover XOSPATA® (gilteritinib), a treatment for FLT3 mutation‐positive relapsed or refractory (R/R) acute myeloid leukemia (AML). See Important Safety Information including BOXED WARNING.

See how XOSPATA® (gilteritinib) works differently than traditional chemotherapy to treat relapsed or refractory (R/R) acute myeloid leukemia with FLT3 mutation.

Get answers to your frequently asked questions about relapsed or refractory FLT3m+ acute myeloid leukemia and XOSPATA® (gilteritinib). See Important Safety Information including BOXED WARNING.

Learn about relapsed or refractory FLT3 mutation‐postive acute myeloid leukemia and XOSPATA® (gilteritinib). See Important Safety Information including BOXED WARNING.

Learn about XOSPATA® (gilteritinib) dosing and administration information. See Important Safety Information including BOXED WARNING.

People in the study were positive for a FLT3 mutation, as determined by a bone marrow or blood test. The final set of results in the study compared the rate of overall survival in 247 people who had taken XOSPATA with 124 people who received chemotherapy.

Information about testing for FLT3 mutations in acute myeloid leukemia (AML). See Important Safety Information including BOXED WARNING.

See XOSPATA® (gilteritinib) patient assistance options, including the XOSPATA® Copay Card Program. See Important Safety Information including BOXED WARNING.

Your healthcare provider may tell you to decrease your dose, temporarily stop, or completely stop taking XOSPATA if you develop certain side effects during treatment with XOSPATA.

XOSPATA is a prescription medicine used to treat adults with acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation when the disease has come back or has not improved after previous treatment (s).